Renin-angiotensin-system-acting agents - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical worsening 0.88 [0.44, 1.76]< 127%3 studies (- / 3)63.8 %criticalnot evaluable very lowcrucial-
death or transfer to ICU 0.29 [0.11, 0.79]< 10%1 study (- / 1)99.2 %seriousnot evaluable lowcrucial-
deaths 0.73 [0.49, 1.10]< 139%5 studies (- / 5)93.5 %criticalnot evaluable very lowcrucial-
deaths (time to event analysis only) 0.97 [0.81, 1.16]< 10%1 study (- / 1)63.0 %seriousnot evaluable lowcrucial-
hospitalization 0.77 [0.53, 1.13]< 10%1 study (- / 1)90.8 %seriousnot evaluable lowimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 87,95,94,90,91,97 94, 95, 97